TrialAmerican heart journal2017
The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial.
Carolyn Y Ho et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
20 papers cite it
this paperpooled ittrialcites it